ClinicalTrials.gg
CompletedNCT01130532Updated Jan 4, 2013Results posted

A Study in Erectile Dysfunction

A Phase 4 interventional study of Tadalafil and Placebo in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 40 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-04.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
623
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
8th of 56
623 · median 199
Started
2010
with 2 others
Phase 4
26 of 57
3 open now
Registered
28th of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 8th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2010, is one of 26 in phase 4, and was the 28th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Erectile Dysfunction
  • ED
  • Impotence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 3-month history of erectile dysfunction (ED).
  • Are able to read, understand and provide signed .
  • Have an International Index of Erectile Function-Erectile Function (IIEF-EF) domain score that is greater than or equal to 17 and less than 26 at screening.
  • Have been taking a maximum dose of sildenafil citrate (100 milligram [mg]), vardenafil (20 mg), or tadalafil (20 mg) on as needed basis for at least one month prior to screening.
  • Anticipate having the same female sexual partner during the study who is willing to participate in the required number of sexual intercourse attempts and complete study measures during the study.
  • Agree to make at least four sexual intercourse attempts during both the 4-week as needed run-in period and the 4-week non-drug run-in period.
  • Agree not to use any other erectile dysfunction (ED) treatment, including herbal therapy during the 4-week non-drug, run-in, the double-blind treatment period, the open label period and for 96 hours after the end of the study.

Partner Inclusion Criteria:

  • Are female and at least 18 years of age at screening.
  • Anticipate having the same male study subject as her sexual partner during the study.
  • Able to read, understand and provide signed informed consent.
  • Agree to make the required number of sexual intercourse attempts with the male sexual study partner during the study.
  • Willing to participate in recording responses to the treatment satisfaction scale.

Exclusion criteria

Exclusion Criteria:

  • Have an IIEF-EF domain score of greater than or equal to 26 at screening.
  • Prior ineffective treatment with (or nonresponder to) any PDE5 Inhibitor
  • Have previously used or are currently using any PDE5 inhibitor once daily.
  • Present with ED caused by other primary disorders or ED caused by untreated/inadequately treated endocrine disease.
  • Partner unwilling to complete all study requirements.
  • History of radical prostatectomy or other pelvic surgery or penile implant, or a penile deformity, in the opinion of the investigator
  • Exhibit evidence of clinically significant renal insufficiency or hepatobiliary disease, or significant cardiac history as determined by the investigator
  • Currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens
  • Have previously completed or withdrawn from this study or any other study investigating tadalafil for once-daily use.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
623 participants (actual)

Study arms

  • Active comparator
    2.5 milligram (mg) titrated to 5 mg Tadalafil

    2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks

    Drug: Tadalafil

  • Active comparator
    5 mg Tadalafil

    5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks

    Drug: Tadalafil

  • Placebo comparator
    Placebo

    for 12 weeks

    Drug: Placebo

Interventions

  • Administer orally

    Also known as: Cialis, LY450190

  • DrugPlacebo

    Administer orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)

    Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of double-blind treatment period (Period III).

    Time frame: Baseline through 12 weeks

Secondary outcomes

  1. Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score

    Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  2. Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score

    Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  3. Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score

    Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  4. Change From Baseline to 12-Week in Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 1-5

    Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient

    The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  6. Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint

    The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.

    Time frame: Week 12

  7. Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)

    Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  8. Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner

    The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

    Time frame: Baseline, 12 weeks

  9. Treatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint

    The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.

    Time frame: Week 12

  10. Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks

    Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of open-label extension treatment period (Period IV).

    Time frame: 12 weeks through 16 weeks

  11. Change From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score

    Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.

    Time frame: 12 weeks and 16 weeks

  12. Change From Week 12 to Week 16 Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 3

    Assessed the percentage of Yes responses to the SEP diary Question 3 "Did your erection last long enough for you to have successful intercourse?" from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).

    Time frame: 12 weeks and 16 weeks

07

Results

Posted Jan 4, 2013

Participant flow

Period III (Weeks 0-12)
Participant flow — Period III (Weeks 0-12)
Milestone2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlacebo5 mg Tadalafil Open-Label Extension
Started2072072090
Received at least 1 dose of study drug2052052070
Completed1861891900
Not completed2118190
Withdrew: Adverse event3320
Withdrew: Entry criteria not met4240
Withdrew: Lack of efficacy2010
Withdrew: Lost to follow-up2230
Withdrew: Protocol violation0010
Withdrew: Sponsor decision3420
Withdrew: Withdrawal by subject7760
Period IV (Weeks 13-16)
Participant flow — Period IV (Weeks 13-16)
Milestone2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlacebo5 mg Tadalafil Open-Label Extension
Started000562
Received at least 1 dose of study drug000546
Completed000552
Not completed00010
Withdrew: Adverse event0001
Withdrew: Entry criteria not met0001
Withdrew: Lost to follow-up0005
Withdrew: Withdrawal by subject0003

Outcome measures

PrimaryPercentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)

Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of double-blind treatment period (Period III).

Time frame:
Baseline through 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)
percentage of participants2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)38.739.612.1
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · Fisher Exact · p = <0.001
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · Fisher Exact · p = <0.001
SecondaryChange From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score

Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score7.9 ± 0.498.1 ± 0.491.8 ± 0.49
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 6.1
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 6.2
SecondaryChange From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score

Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score2.8 ± 0.212.6 ± 0.210.6 ± 0.21
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 2.1
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 2.0
SecondaryChange From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score

Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score2.4 ± 0.162.4 ± 0.160.6 ± 0.16
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 1.7
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 1.7
SecondaryChange From Baseline to 12-Week in Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 1-5

Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline to 12-Week in Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 1-5
percentage of "yes" responses2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Question 1: Able to Achieve Erection12.2 ± 1.6311.4 ± 1.621.8 ± 1.62
Question 2: Able to Insert26.2 ± 2.2526.1 ± 2.236.9 ± 2.23
Question 3: Successful Intercourse37.3 ± 2.5239.4 ± 2.5012.6 ± 2.51
Question 4: Satisfied with Hardness44.2 ± 2.7342.8 ± 2.7011.5 ± 2.71
Question 5: Overall Satisfaction with Experience43.6 ± 2.7041.2 ± 2.6810.6 ± 2.68
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 1. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 10.4
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 1. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 9.6
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 2. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 19.3
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 2. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 19.3
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 3. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 24.7
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 3. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 26.8
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 4. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 32.7
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 4. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 31.3
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 5. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 33.0
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for Question 5. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 30.5
SecondaryChange From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient

The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Confidence to complete sexual activity27.0 ± 1.7829.2 ± 1.783.8 ± 1.77
Ease of erection24.0 ± 1.6924.7 ± 1.694.1 ± 1.68
Pleasure from sexual activity22.6 ± 1.5822.7 ± 1.583.3 ± 1.57
Erectile function satisfaction31.0 ± 1.8233.6 ± 1.814.9 ± 1.81
Satisfaction with orgasm25.6 ± 1.9026.3 ± 1.896.2 ± 1.88
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 23.1
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 25.4
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 19.9
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 20.6
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 19.3
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 19.5
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 26.0
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 28.7
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 19.3
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 20.1
SecondaryTreatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint

The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint53.7 ± 1.9855.9 ± 1.9824.8 ± 1.97
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 28.9
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 31.0
SecondaryChange From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)

Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)1.2 ± 0.081.3 ± 0.080.3 ± 0.08
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 0.9
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 1.0
SecondaryChange From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner

The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Confidence to complete sexual activity23.7 ± 2.0127.2 ± 1.992.0 ± 1.99
Ease of erection23.1 ± 1.7625.3 ± 1.750.7 ± 1.75
Pleasure from sexual activity18.2 ± 1.6918.5 ± 1.681.3 ± 1.68
Erectile function satisfaction28.6 ± 1.8428.5 ± 1.833.4 ± 1.83
Satisfaction with orgasm18.7 ± 2.0621.0 ± 2.053.6 ± 2.04
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 21.7
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for confidence to complete sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 25.2
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 22.3
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for ease of erection. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 24.5
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 16.9
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for pleasure from sexual activity. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 17.2
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 25.2
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for erectile function satisfaction. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 25.1
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 15.1
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANCOVA · p = <0.001 (P-value is for satisfaction with orgasm. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 17.3
SecondaryTreatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint

The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Treatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period III)5 mg Tadalafil (Period III)Placebo (Period III)
Treatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint52.5 ± 1.9755.7 ± 1.9627.5 ± 1.96
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 25.1
  • 5 mg Tadalafil (Period III) vs Placebo (Period III) · ANOVA · p = <0.001 (Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.) · Ls mean difference: 28.2
SecondaryPercentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks

Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of open-label extension treatment period (Period IV).

Time frame:
12 weeks through 16 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks
percentage of participants2.5 mg Titrated to 5 mg Tadalafil (Period IV)5 mg Tadalafil (Period IV)Placebo (Period IV)
Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks54.559.862.8
SecondaryChange From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score

Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.

Time frame:
12 weeks and 16 weeks
Reported as:
Mean · units on a scale
Change From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score
units on a scale2.5 mg Titrated to 5 mg Tadalafil (Period IV)5 mg Tadalafil (Period IV)Placebo (Period IV)
End of Week 1222.4 ± 6.7122.5 ± 7.0716.0 ± 7.39
End of Week 1624.1 ± 6.4424.2 ± 6.4624.4 ± 6.73
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period IV) · Paired t-test · p = <0.001 (Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.)
  • 5 mg Tadalafil (Period IV) · Paired t-test · p = <0.001 (Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.)
  • Placebo (Period IV) · Paired t-test · p = <0.001 (Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.)
SecondaryChange From Week 12 to Week 16 Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 3

Assessed the percentage of Yes responses to the SEP diary Question 3 "Did your erection last long enough for you to have successful intercourse?" from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).

Time frame:
12 weeks and 16 weeks
Reported as:
Mean · percentage of "yes" responses
Change From Week 12 to Week 16 Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 3
percentage of "yes" responses2.5 mg Titrated to 5 mg Tadalafil (Period IV)5 mg Tadalafil (Period IV)Placebo (Period IV)
End of Week 1268.3 ± 38.2569.0 ± 37.8843.1 ± 39.03
End of Week 1675.0 ± 34.4975.5 ± 34.8980.0 ± 34.37
Statistical analysis
  • 2.5 mg Titrated to 5 mg Tadalafil (Period IV) · Paired t-test · p = 0.002 (Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.)
  • 5 mg Tadalafil (Period IV) · Paired t-test · p = 0.004 (Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.)
  • Placebo (Period IV) · Paired t-test · p = <0.001 (Comparison of Week 16 to Week 12. Sequential gatekeeping strategies were applied for multiplicity control and the p-value was not adjusted.)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2.5 mg Titrated to 5 mg Tadalafil—1/205 (0.5%)46/205 (22.4%)
5 mg Tadalafil—1/205 (0.5%)68/205 (33.2%)
Placebo—1/207 (0.5%)50/207 (24.2%)
5 mg Tadalafil Open-Label Extension—3/546 (0.5%)23/546 (4.2%)
Most frequent serious events
Most frequent serious events
Event2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlacebo5 mg Tadalafil Open-Label Extension
Small intestinal obstructionGastrointestinal disorders0/2051/2050/2070/546
Chest discomfortGeneral disorders1/2050/2050/2070/546
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders1/2050/2050/2070/546
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2050/2051/2070/546
Cholecystitis acuteHepatobiliary disorders0/2050/2050/2071/546
Meningitis viralInfections and infestations0/2050/2050/2071/546
SyncopeNervous system disorders0/2050/2050/2071/546
Most frequent other events
Showing 10 of 164
Most frequent other events
Event2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlacebo5 mg Tadalafil Open-Label Extension
HeadacheNervous system disorders4/2059/2057/2074/546
DyspepsiaGastrointestinal disorders2/2056/2051/2070/546
Back painMusculoskeletal and connective tissue disorders3/2056/2051/2072/546
DiarrhoeaGastrointestinal disorders2/2053/2053/2070/546
BronchitisInfections and infestations3/2052/2050/2070/546
NasopharyngitisInfections and infestations2/2053/2051/2070/546
SinusitisInfections and infestations1/2053/2051/2072/546
Upper respiratory tract infectionInfections and infestations3/2052/2053/2070/546
Pain in extremityMusculoskeletal and connective tissue disorders1/2053/2050/2070/546
DizzinessNervous system disorders1/2053/2051/2071/546

Baseline characteristics

Age Continuous
Age Continuous(years)2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlaceboTotal
Mean57.3 ± 10.6858.1 ± 10.3657.6 ± 10.1757.6 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlaceboTotal
Female0000
Male207207209623
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlaceboTotal
Hispanic or Latino810927
Not Hispanic or Latino199197200596
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlaceboTotal
American Indian or Alaska Native0202
Asian2248
Native Hawaiian or Other Pacific Islander0011
Black or African American29243588
White173177167517
More than one race3126
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)2.5 mg Titrated to 5 mg Tadalafil5 mg TadalafilPlaceboTotal
United States199195191585
Canada8111837
Puerto Rico0101
08

Study locations

40 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newport Beach, California 92660, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spring Valley, California 91978, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tarzana, California 91356, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Britain, Connecticut 06052, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aventura, Florida 33180, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33316, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oviedo, Florida 32765, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Meridian, Idaho 83646, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nampa, Idaho 83686, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lansing, Kansas 66043, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haverhill, Massachusetts 01830, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Troy, Michigan 48085, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toms River, New Jersey 08753, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden City, New York 11530, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poughkeepsie, New York 12601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, North Carolina 28025, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wilmington, North Carolina 28401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fargo, North Dakota 58103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyndhurst, Ohio 44124, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bala Cynwyd, Pennsylvania 19004, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anderson, South Carolina 29621, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greer, South Carolina 29651, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mt. Pleasant, South Carolina 29464, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37920, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78731, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78258, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Clinton, Utah 84015, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bellevue, Washington 98007, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98166, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99220, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Langley, British Columbia V3A 4H9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Victoria, British Columbia V8T 5G1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Burlington, Ontario L7N 3V2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    North York, Ontario M3B 3S6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H2X 1N8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saskatoon, Saskatchewan S7K 7H9, Canada
09

References and documents

Publications

  • Kim E, Seftel A, Goldfischer E, Baygani S, Burns P. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2015 Feb;31(2):379-89. doi: 10.1185/03007995.2014.989317. Epub 2014 Dec 2. PubMed 25455432 ↗
  • Kim ED, Seftel AD, Goldfischer ER, Ni X, Burns PR. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med. 2014 Mar;11(3):820-30. doi: 10.1111/jsm.12253. Epub 2013 Jul 10. PubMed 23841532 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2010
First posted
May 26, 2010
Start
Aug 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Jan 4, 2013
Last update
Jan 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01130532
Responsible party
Sponsor
First posted
May 26, 2010
Start date
Aug 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jan 4, 2013
Last update
Jan 4, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion